Gleiter, Christoph H.

[["dc.bibliographiccitation.firstpage","253"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","European Journal of Clinical Pharmacology"],["dc.bibliographiccitation.lastpage","257"],["dc.bibliographiccitation.volume","58"],["dc.contributor.author","Meyer-Barner, M."],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Schreeb, K. H."],["dc.contributor.author","Gleiter, Christoph H."],["dc.date.accessioned","2018-11-07T10:20:36Z"],["dc.date.available","2018-11-07T10:20:36Z"],["dc.date.issued","2002"],["dc.description.abstract","Objective: Little information on the population pharmacokinetics of the tricyclic antidepressant doxepine and its pharmacologically active metabolite desmethyldoxepine is available. However, a more individualised drug therapy may be feasible if the influence of various patient characteristics on plasma concentration was known. Patients and methods: We retrospectively analysed pharmacokinetic therapeutic drug-monitoring data in 114 psychiatric patients (79 females, 35 males) treated with doxepine for a period of 22-306 days, mostly due to major depression. The data were analysed using the computer program NONMEM. For both, doxepine and its metabolite desmethyldoxepine, a one-compartment model was chosen. Pharmacokinetic parameters clearance (CL/F) and volume of distribution (V/F) of doxepine and desmethyldoxepine were modelled in terms of both random and fixed effects. Results: The fit of the model to the concentration-time data was significantly improved when V/F was expressed as a function of weight (P < 0.05) and CL/F as a function of age (P < 0.05). Co-medication that inhibits P-450 isoenzymes lowered CL/F of doxepine by 15%. Conclusion: The analysis indicates that the factors age and, to some extent, body weight may be a guidance for individual doxepine dose regimens, which however needs confirmation in prospective clinical trials linking pharmacokinetics and therapeutic effect. Co-medication may represent only a minor important covariate."],["dc.identifier.doi","10.1007/s00228-002-0448-3"],["dc.identifier.isi","000177241500005"],["dc.identifier.pmid","12136371"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41918"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0031-6970"],["dc.title","Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","592"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","British Journal of Clinical Pharmacology"],["dc.bibliographiccitation.lastpage","603"],["dc.bibliographiccitation.volume","54"],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Freudenthaler, S."],["dc.contributor.author","Hofmann, U."],["dc.contributor.author","Schaeffeler, E."],["dc.contributor.author","Mikus, G."],["dc.contributor.author","Schwab, M."],["dc.contributor.author","Prange, H. W."],["dc.contributor.author","Gleiter, Christoph H."],["dc.contributor.author","Brockmoeller, Juergen"],["dc.date.accessioned","2018-11-07T09:43:46Z"],["dc.date.available","2018-11-07T09:43:46Z"],["dc.date.issued","2002"],["dc.description.abstract","Aims Concentrations in the cerebrospinal fluid (CSF) are a useful approximation to the effect site for drugs like morphine. However, CSF samples, are available only in rare circumstances. If they can be obtained they may provide important insights into the pharmacokinetics/pharmacodynamics of opioids. Methods Nine neurological and neurosurgical patients (age 19-69 years) received 0.5 mg kg(-1) morphine sulphate pentahydrate as an intravenous infusion over 30 min. Plasma and CSF were collected for up to 48 h. Concentration time-course and interindividual variability of morphine (M), morphine-3-glucuronide (M3G) and morphine-6 glucuronide (M6G) were analysed using population pharmacokinetic modelling. Results While morphine was rapidly cleared from plasma (total clearance = 1838 ml min(-1) (95% CI 1668, 2001 ml min(-1) )) the glucuronide metabolites were eliminated more slowly (clearance M3G = 44.5 ml min(-1) (35.1, 53.9 ml min(-1) ), clearance M6G = 42.1 ml min(-1) (36.4, 47.7 ml min(-1) )) and their clearance could be described as a function of creatinine clearance. The central volumes of distribution were estimated to be 12.7 l (11.1, 14.3 l) for morphine. Transfer from the central compartment into the CSF was also rapid for M and considerably slower for both glucuronide metabolites. Maximum concentrations were achieved after 102 min (M), 417 min (M3G) and 443 min (M6G). A P-glycoprotein exon 26 polymorphism previously found to be linked with transport activity could be involved in CSF accessibility, since the homozygous mutant genotype was associated (P < 0.001) with high maximum CSF concentrations of M but not M3G or M6G. Conclusions From the population pharmacokinetic model presented, CSF concentration profiles can be derived for M, M3G and M6G on the basis of dosing information and creatinine clearance without collecting CSF samples. Such profiles may then serve as the link between dose regimen and effect measurements in future clinical effect studies."],["dc.identifier.doi","10.1046/j.1365-2125.2002.t01-1-01689.x"],["dc.identifier.isi","000179909500005"],["dc.identifier.pmid","12492606"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34251"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Blackwell Publishing Ltd"],["dc.relation.issn","0306-5251"],["dc.title","Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","885"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","The American Journal of Psychiatry"],["dc.bibliographiccitation.lastpage","890"],["dc.bibliographiccitation.volume","156"],["dc.contributor.author","Kornhuber, Johannes"],["dc.contributor.author","Schultz, Andreas"],["dc.contributor.author","Wiltfang, Jens"],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Gleiter, Christoph H."],["dc.contributor.author","Zöchling, Robert"],["dc.contributor.author","Boissl, Karl-Werner"],["dc.contributor.author","Leblhuber, Friedrich"],["dc.contributor.author","Riederer, Peter"],["dc.date.accessioned","2017-09-07T11:44:42Z"],["dc.date.available","2017-09-07T11:44:42Z"],["dc.date.issued","2014"],["dc.description.abstract","OBJECTIVE: After discontinuation of neuroleptic drugs, their antipsychotic and antiparkinsonian effects are still present for a prolonged period. It is not known whether the extended effects of neuroleptic drugs in humans are due to the continued presence of drug in brain tissue or to long-lasting drug-induced physiologic changes. The aim of this study was to directly examine haloperidol concentrations in human brain tissue in relation to drug-free time. METHOD: Haloperidol concentrations were measured in five regions (temporal cortex, cingulate gyrus, caudate nucleus, dentate nucleus, corpus callosum) of the postmortem brains of 11 patients previously treated with haloperidol. Haloperidol was analyzed by means of high-performance liquid chromatography with ultraviolet detection. The half-life in brain tissue was estimated by a population kinetic analysis. RESULTS: Haloperidol concentrations in the human brain tissue were 10–30 times higher than optimal serum concentrations used in the treatment of schizophrenia. Haloperidol concentrations appeared to be homogeneously distributed across different brain areas within a single patient. There was no apparent relation between duration of treatment and mean haloperidol concentration. Higher doses of haloperidol seemed to be related to higher concentrations in brain tissue. The elimination half-life from brain tissue was calculated to be 6.8 days. CONCLUSIONS: The results may have implications for clinical treatment decisions and the design of clinical research protocols. Patients exposed to haloperidol cannot be considered to be free of residual effects of the drug for a number of weeks after withdrawal."],["dc.identifier.doi","10.1176/ajp.156.6.885"],["dc.identifier.gro","3151727"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/8548"],["dc.language.iso","en"],["dc.notes.status","public"],["dc.notes.submitter","chake"],["dc.relation.issn","0002-953X"],["dc.title","Persistence of Haloperidol in Human Brain Tissue"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","315"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"],["dc.bibliographiccitation.lastpage","325"],["dc.bibliographiccitation.volume","742"],["dc.contributor.author","Pilz, Jürgen"],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Gleiter, Christoph H."],["dc.date.accessioned","2021-06-01T10:50:16Z"],["dc.date.available","2021-06-01T10:50:16Z"],["dc.date.issued","2000"],["dc.description.abstract","We established a method for the detection of free and total (free and bound) malondialdehyde (MDA) in human plasma samples after derivatisation with 2,4-dinitrophenylhydrazine (DNPH). Free MDA was prepared by perchloric acid deproteinisation whereas an alkaline hydrolysation step for 30 min at 60 degrees C was introduced prior to protein precipitation for the determination of total MDA. Derivatisation was accomplished in 10 min at room temperature subsequently chromatographed by HPLC on a reversed-phase 3 mu m C-18 column with UV detection (310 nm). The detection limit was 25 pmol/ml for free and 0.3 nmol/ml for total MDA. The recovery of MDA added to different human plasma samples was 93.6% (n=11; RSD 7.1%) for the hydrolysation procedure. In samples from 12 healthy volunteers who underwent a hypoxic treatment (13% O-2 for 6 h) we estimated a baseline value of total MDA of 2.16 nmol/ml (SD 0.29) (ambient air) with a significant increase to 2.92 (nmol/ml, SD 0.57; P=0.01) after the end of this physiological oxidative stress challenge. Plasma values of free MDA in these samples were close to our detection limit. The presented technique can easily performed with an isocratic HPLC apparatus and provides highly specific results for MDA as do sophisticated GC-MS methods. (C) 2000 Elsevier Science B.V. All rights reserved."],["dc.identifier.doi","10.1016/S0378-4347(00)00174-2"],["dc.identifier.isi","000087713300011"],["dc.identifier.pmid","10901136"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86593"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","0378-4347"],["dc.title","Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","PII S0731-7085(02)00011-0"],["dc.bibliographiccitation.firstpage","147"],["dc.bibliographiccitation.issue","1-2"],["dc.bibliographiccitation.journal","Journal of Pharmaceutical and Biomedical Analysis"],["dc.bibliographiccitation.lastpage","152"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Steinmetz, Hannelore"],["dc.contributor.author","Kramer, Skaidrit"],["dc.contributor.author","Gleiter, Christoph H."],["dc.date.accessioned","2021-06-01T10:50:17Z"],["dc.date.available","2021-06-01T10:50:17Z"],["dc.date.issued","2002"],["dc.description.abstract","A new method for the determination of fenoterol is described, which uses HPLC separation with fluorescence detection. Dobutamine is employed as an internal standard. The separation was achieved on a short reversed phase column with a mobile phase consisting of water, acetonitrile and methanol. Prior to chromatography both analytes are derivatized with 9-chloroformyl-carbazole. Isolation of the analytes from plasma is carried out by liquid-liquid extraction into 2-butanol after protein precipitation with acetonitrile. The method is capable of estimating fenoterol concentrations in the sub-nanogram per ml range with sufficient accuracy and precision. The determination of fenoterol can now be carried out in the average laboratory without radiolabelled material. (C) 2002 Elsevier Science B.V. All rights reserved."],["dc.identifier.doi","10.1016/S0731-7085(02)00011-0"],["dc.identifier.isi","000176493900015"],["dc.identifier.pmid","12062673"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86600"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Pergamon-elsevier Science Ltd"],["dc.relation.issn","0731-7085"],["dc.title","Determination of fenoterol in human plasma by HPLC with fluorescence detection after derivatization"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","153"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","International Clinical Psychopharmacology"],["dc.bibliographiccitation.lastpage","161"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","George, A."],["dc.contributor.author","Jestrabeck, C."],["dc.contributor.author","Opitz, M."],["dc.contributor.author","Bartmann, U."],["dc.contributor.author","Gleiter, Christoph H."],["dc.contributor.author","Meineke, Ingolf"],["dc.contributor.author","Roed, I. S."],["dc.contributor.author","Ruther, Eckart"],["dc.contributor.author","Hajak, Goran"],["dc.date.accessioned","2018-11-07T10:53:42Z"],["dc.date.available","2018-11-07T10:53:42Z"],["dc.date.issued","2000"],["dc.description.abstract","In patients with panic disorder and/or agoraphobia (PDA) an increased sensitivity of central 5-HT2C receptors and a decreased responsiveness of 5-HT1A receptors has been postulated. In the present study, neuroendocrine challenges were performed using oral doses of the non-selective 5-HT2C agonist m-chlorophenylpiperazine (m-CPP) (0.4mg/kg), the selective 5-HT1A antagonist ipsapirone (0.3mg/kg), and placebo in 40 patients with PDA and 12 healthy controls in order to compare 5-HT2C and 5-HT1A-specific psychobehavioural and neuroendocrine response patterns. At baseline, all psychobehavioural variables and the plasma concentration of noradrenaline (NE) were significantly increased in the patient group compared to the controls. The administration of m-CPP or ipsapirone was followed by comparable psychological symptoms and, in 55% of all patients, panic attacks. In comparison to the control subjects, patients were characterized by significantly higher psychological reactions to both challenge agents and a significantly higher NE response to m-CPP. In the patient group, there was also a trend towards an increased cortisol response after administration of m-CPP and a decreased cortisol and hypothermia response after administration of ipsapirone compared to the control group. The neuroendocrine findings of our study support earlier reports of opposite changes in the responsiveness of 5-HT2C- and 5-HT1A-related receptors in PDA patients. The behavioural hypersensitivity to both, m-CPP and ipsapiron, shows that the provocation of anxiety and other psychological symptoms might be influenced by cognitive factors. (C) 2000 Zippincott Williams & Wilkins."],["dc.identifier.doi","10.1097/00004850-200015030-00004"],["dc.identifier.isi","000086955900004"],["dc.identifier.pmid","10870873"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49403"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","0268-1315"],["dc.title","Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]